Objective. We aim to study the impact of preoperative opioid dosage on postoperative length of stay (LOS) in patients undergoing thoracic spinal cord stimulator (SCS) placement surgery as a primary objective. Secondary objectives of this study include investigating patient-controlled analgesia (PCA) usage and postoperative complications like fever in relation to patients' preoperative opioid dosage and postoperative LOS.
Abstract
Objective. We aim to study the impact of preoperative opioid dosage on postoperative length of stay (LOS) in patients undergoing thoracic spinal cord stimulator (SCS) placement surgery as a primary objective. Secondary objectives of this study include investigating patient-controlled analgesia (PCA) usage and postoperative complications like fever in relation to patients' preoperative opioid dosage and postoperative LOS.
Methods. A total of 47 patients who underwent thoracic SCS for first time were retrospectively studied through chart review. These patients were categorized into two groups, with Group I patients taking a morphine equivalent dose (MED) of less than 100 mg and Group II patients taking an MED of more than 100 mg preoperatively.
Results. Group I had 22 patients, and Group II had 25 patients. The average age in Group I was 53.45 years, and the average age in Group II was 50.16 years. There were seven males (38%) and 15 females (62%) in Group I, and in Group II there were 11 males (44%) and 14 females (56%). The average LOS in both groups was two days. In Group I, there were 16 patients (73%) who had an LOS of one day and six patients (27%) who had an LOS of more than one day, and in Group II there were 11 patients (44%) who had an LOS of less than one day and 14 patients (56%) who had an LOS of more than one day, with a P value of 0.047. On univariate analysis, postoperative fever and PCA usage correlated with longer hospital stay, with a P value of < 0.001.
Introduction
Low back pain (LBP) is prevalent in our society; it is the second most common cause of disability and lost workdays [1, 2] . The mainstay of treatment includes physical therapy and medication management strategies. Opioid therapy is commonly used in the United States to treat chronic low back pain, and the use of opioids for chronic pain has been increasing [3] . In addition, there has been an increasing trend of spinal injections and surgical therapies for patients with chronic LBP [4, 5] . Spinal cord stimulation (SCS) is a treatment option for a subset of patients with intractable chronic LBP and leg pain.
Many patients who undergo spinal cord stimulator surgery are on chronic opioid therapy. There is evidence that chronic opioid therapy may contribute to longer hospital stays following surgery [6] . The primary aim of this study is to assess the relationship of preoperative V C 2017 American Academy of Pain Medicine. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com opioid dosage to postoperative length of stay (LOS) in the hospital in patients undergoing thoracic SCS surgery. Secondary aims are to assess the effect of opioid dose on postoperative fever and postoperative patientcontrolled analgesia (PCA) devise use.
Methods
Under institutional review board approval, we performed a retrospective review including patients who underwent primary thoracic SCS surgery between 2009 and 2014. Indications for SCS surgery were postlaminectomy syndrome from previous lumbar laminectomy, microdiscectomy, or fusion in all patients except one who had complex regional pain syndrome (CRPS). All patients had successful trials with percutaneous SCS leads by pain specialists. After a thorough preoperative workup, all patients were operated upon under general anesthesia. Patients were positioned prone, and under fluoroscopic guidance T9-T10 laminotomies were performed. Paddle electrodes were placed, and stimulation coverage was confirmed with neurophysiological monitoring. A separate incision was made in the gluteal region, and a pocket was created for battery insertion. After successful placement of the paddle lead, wires were tunneled subcutaneously and connected to the battery. The connections were then tested before wounds were closed in layers.
Revision surgeries were excluded from analysis. Data on duration of patients' symptoms were excluded from analysis as well because they were not available accurately for all patients. Patients' preoperative cumulative daily opioid dosages were converted into morphine equivalent dose (MED) by using an online opioid conversion calculator (http://agencymaldirectors.Wa.gov/ mobile.html). Previous studies have considered MEDs above 100 mg a high dose due to the associated risks to a patient's health [7, 8] . Accordingly, patients were then divided into two groups, Group I with MED < 100 mg and Group II with MED > 100 mg.
The primary outcome consisted of postoperative length of stay in the hospital, and the secondary outcome measures consisted of patient-controlled analgesia (PCA) usage and postoperative complications like fever. Statistical analysis was performed using IBM SPSS Statistics 2012. Data were analyzed with chi-square and the Mann-Whitney test, for which a P value of less than 0.05 was considered statistically significant.
Results
The study group consisted of 47 patients, of which 22 patients were in cohort I (MED < 100) and 25 were in cohort II (MED > 100). Demographic data are summarized in Table 1 . Postoperative pain management regimens were similar in both groups, including a combination of opioids (morphine, fentanyl, dilaudid), PCA or injection on a PRN basis, oral immediate and extended-release opioids, pregabalin, gabapentin, and acetaminophen.
The mean LOS in cohort I was 1.55 days (1-4 days), and in cohort II the LOS was 2.04 days (1-5 days). There was a statistically significant difference, with 27% of cohort I patients with an LOS greater than one day compared with 56% of cohort II patients (P ¼ 0.047), seen in Table 1 . The distribution of each individual's corresponding MED and LOS is presented in Figure 1 . Postoperative fever was seen in 9% of cohort I and 32% of cohort II; these numbers are included in Table  1 . Table 2 shows that all 10 patients who had postoperative fever had an LOS of greater than one day (P < 0.001). PCA usage was seen in 4.5% of cohort I and in 36% of cohort II, characterized by Table 1 . Table  3 demonstrates that among the entire study group, 45% of patients who had an LOS greater than one day also had PCA usage (P ¼ 0.001). Figure 2 represents the results of a Mann-Whitney test, indicating that patients who used PCA had a significantly higher median MED (P ¼ 0.001). Patients who experienced postoperative fever are highlighted on a distribution plot with each patient's MED and LOS in Figure 3 , showing cohort II's higher proportion of patients with postoperative fevers. In order to eliminate potential biases involved with these clinical outcomes, a multivariate analysis with logistic regression proved no significance for additional covariates, including gender and age.
A history of smoking, described in Table 1 , was seen in 14% of cohort I and 40% of cohort II and was not statistically significant. Other medical comorbidities, including hypertension, diabetes mellitus, chronic obstructive pulmonary disease, and high body mass index, were looked at and were not significant. There was only one complication in the form of a superficial wound infection in cohort II.
Discussion
According to one source's findings, opioid analgesic sales have increased seven-fold from 1997 to 2010 [9] . The United States accounts for 99% and 83% of the world's supply of hydrocodone and oxycodone, respectively [10] . While there has been no consensus on what constitutes a low dose or high dose of morphine, some studies have considered a daily MED of 100 mg or higher to be a high dose due to the major risk of adverse effects, overdose, and mortality [7, 8] . Recent opioid prescription guidelines for treating chronic pain incorporate a more stringent approach in order to lower the risk of overdose, suggesting that clinicians ought to reassess an opioid treatment's efficacy for individual patients before raising their opioid dosages above a daily MED of 50 mg and that they should avoid treatments that exceed a daily MED of 90 mg without carefully justifying the decision [11] . Additionally, chronic opioid therapy is linked to a higher prevalence for meeting the standards of clinical depression [12] . The length of the recovery period and direct outcome of total hip arthroplasty procedures were negatively impacted by the use of opioids prior to the operation; the risk of opioid-induced hyperalgesia may affect clinical results [13] . Additionally, there is evidence that patients who are on higher dosages of opioids prior to their operation have a significantly longer length of stay in the hospital following orthopedic surgery [6] . As such, we preformed this retrospective analysis of patients who underwent thoracic SCS surgery between 2009 and 2014, which was performed in order to determine the relationship between preoperation opioid dosage and LOS as well as complications.
This study's results suggest that a patient's preoperative opioid dosage plays an important role in the length of their hospital stay-with a meaningful relationship between the dosage groups and the length of a patient's hospital stay (P ¼ 0.047). As a secondary objective, an association between higher preoperative dosages and PCA usage (P < 0.001) was additionally found. Patients with higher preoperative opioid dosages had greater odds of experiencing postoperative fever and a longer hospital stay. Considering the connection between preoperative opioid dosages and length of a patient's Effect of Preoperative Opioid Dosage Figure 2 Comparison graph of patients with patient-controlled analgesia (PCA) having higher median morphine equivalent dose. MED ¼ morphine equivalent dose; PCA ¼ patient-controlled analgesia. hospital stay, it is important to note the significant relationships between length of a patient's hospital stay and their tendency to use PCA (P < 0.001), as well as their postoperative fever likelihood (P < 0.001). Patients' gender, age, comorbidities, and smoking status were considered and ruled out as statistically significant covariates for this study's findings.
Length of stay is an advantageous variable to focus on because of the obvious strain this puts on the hospital staff as well as the patients and their families. Exploring the aspects of preoperative care that correlate to how long a patient will spend in the hospital increases awareness for areas capable of progress.
The patients on a higher MED (>100 mg) prior to their thoracic SCS procedure tend to require a longer stay in the hospital after their surgery, consequently increasing a hospital's burdens. These findings are supported by previous evidence surrounding various opioid-related adverse effects that result in a significantly longer length of stay. Constipation, emesis, and confusion are all notable side effects associated with opioid usage; these conditions demand a longer recovery period in the hospital and disrupt the quality of a patient's life [12] .
Although retrospective analysis is a useful tool, it does come with limitations. The statistical evaluation performed on the thoracic SCS patients' chart review serves as evidence of a relationship between the levels of MED prior to surgery and the patient's length of stay in the hospital. Determining a causal relationship would require more verification than what the available information on these patients permits. Furthermore, the data available for analysis through chart documentation are specific to the preoperative opioids and length of hospital stay connected with thoracic SCS surgery. Additional factors that could not be ruled out for their possible contributions to postoperative LOS include the duration of each patient's opioid analgesic treatment prior to SCS surgery, analgesic tolerance, consequences of opioid-induced hyperalgesia, as well as other explanations related to cohort II's high MEDs.
Conclusion
The results of our study demonstrate that high-dose opioid therapy prior to spinal cord stimulator implantation surgery may contribute to longer length of hospital stay compared with patients on lower-dose or no opioid therapy. In light of this finding, the surgical team may wish to consider the option of opioid tapering prior to proceeding with spinal cord stimulator implantation surgery. This may require close cooperation with the prescribing provider prior to surgery. Patients with higher preoperative opioids tend to stay longer after thoracic spinal cord stimulator surgery and require PCA more frequently during their postoperative hospital stay. This likely leads to higher cost of care and adds to an existing health care burden. Multicenter randomized study exploring these primary and secondary objectives in light of the limitations mentioned would be necessary to confirm these findings.
